{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-082477","form_type":"8-K","ticker":"TKNO","cik":"0001850902","company_name":"Alpha Teknova, Inc.","filed_at":"2024-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.913486+00:00","generated_at":"2026-05-31T22:39:34.863570+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Alpha Teknova reports Q2 2024 rev $9.4-9.6M, reaffirms FY guidance $35-38M","bullets":["Q2 2024 total revenue $9.4-9.6M, down 17-18% YoY but up 7-9% adjusting for large prior-year order.","FY 2024 revenue guidance reaffirmed at $35-38M; free cash outflow <$18M.","Headcount reduced >40% from Q2 2022 peak to 169; cash used in Q2 was $3.0-3.4M.","Clinical Solutions customers grew from 34 to 43; Lab Essentials customers from 2,829 to 2,913.","No single direct customer >$1M YTD; full Q2 results expected August 13, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-082477","json":"https://secwatch.observer/filing/0000950170-24-082477.json","markdown":"https://secwatch.observer/filing/0000950170-24-082477.md","text":"https://secwatch.observer/filing/0000950170-24-082477.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850902/000095017024082477/0000950170-24-082477-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850902/000095017024082477/tkno-20240709.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:39:34.863570+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}